NOVOCURE LTD

NVCRNASDAQ

🏆 #1668 by market capEarnings Oct 29US Equity

$17.66▲ $0.38 (+2.14%)

Market closed · at close

1h—

24h▲ 2.1%

7d▲ 10.0%

14d▲ 16.3%

30d▲ 9.8%

1y▲ 55.6%

🏦Market Cap

$2.06B

Small Cap

📈Revenue Growth (YoY)

+8.3%

Slowing

📊Gross Margin

76.1%

High

💵FCF Margin

-3.0%

Thin

⚖️P/S Ratio

2.9x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $17.46 – $17.94
52-Week Range: $9.82 – $21.45
Volume: $2.65B
Avg Volume: $2.93B
Shares Outstanding: 116.4M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $655M
Last Q Revenue: $184M
P/E Ratio: -13.6
P/S Ratio: 2.9x
EPS (TTM): $-1.28
Dividend Yield: 0.00%

Why Investors Own NVCR

✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
✓Healthy economics — 61% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$655M▲ +32.3% YoY

Gross Margin (TTM)

61.4%▲ +3.7% YoY

Operating Income (TTM)

$112M▲ +32.3% YoY

Free Cash Flow (TTM)

$195M▲ +32.3% YoY

About NOVOCURE LTD

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

🦦